FOR IMMEDIATE RELEASE

Contact: Ronald C. Trahan, APR, President, Ronald Trahan Associates Inc., +1-508-816-6730

Stentys expands Scientific Advisory Board (SAB) on heels of reporting successful clinical trial results for world’s first self-expanding stent to treat AMI

Results of clinical study to treat acute myocardial infarction with the Stentys self-expanding stent showed adaptation to vessel growth with perfect apposition

PRINCETON, N.J., and PARIS, Oct. 27, 2009—Medical device pioneer Stentys announced today that it has expanded its Scientific Advisory Board (SAB) by adding five distinguished interventional cardiologists.

The expansion of the Stentys SAB follows closely the disclosure of results on 20 patients participating in the Company’s ‘APPOSITION I’ clinical study—the world’s first to treat patients with acute myocardial infarction (AMI) via a self-expanding stent. The study demonstrated that the coronary vessel expands a few days after treatment as vasospasm is relieved, and that the Stentys stent follows this expansion with perfect apposition.

The additions to the Stentys SAB include: Raoul Bonan, M.D., Associate Professor of Medicine, Montreal University, Quebec, Canada; Roxana Mehran, M.D., New York Presbyterian Hospital/Columbia University Medical Center, New York; Martin T. Rothman, M.D., The London Chest Hospital, London, U.K.; Christian Spaulding, M.D., Ph.D., Cochin Hospital, Paris; and Stefan Verheye, M.D., Ph.D., Antwerp Cardiovascular Institute, Middelheim Hospital, Belgium.

In addition to the five new members, the Stentys SAB includes: Maurice Buchbinder, M.D., The Foundation for Cardiovascular Medicine, La Jolla, Calif.; Eberhard Grube, M.D., Helios Heart Center, Siegburg, Germany; Jean-Claude Laborde, M.D., Glenfield General Hospital, Leicester, UK; Thierry Lefevre, M.D., Institut Hospitalier Jacques Cartier, Massy, France; and Patrick W. Serruys, M.D., Thoraxcenter-Erasmus University, Rotterdam, The Netherlands.

“We are very honored to be advised by some of the most experienced and distinguished interventional cardiologists in the world,” said Gonzague Issenmann, CEO and co-founder of Stentys. “Expansion of our SAB parallels the advancement of our APPOSITION program, which will show the superiority of the Stentys self-expanding stent over a conventional stent to treat AMI.”

About Stentys

Based in Princeton, N.J., and Paris, Stentys intends to make treatment of complex blocked coronary arteries as simple and effective as a conventional stenting procedure. Stentys was co-founded by Gonzague Issenmann and Jacques Séguin, M.D., Ph.D., founder of CoreValve, which was acquired this year by Medtronic for $700 million plus earn-outs.

###